Evaluating the effectiveness and safety of various Tirzepatide dosages in the management of Type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials
ConclusionTZP effectively lowers HbA1c and induces weight loss across its three doses for type 2 diabetes management. The higher dose (15 mg) significantly reduces fasting serum glucose, with increased adverse events observed at higher doses. Dose-specific patterns for adverse effects emphasize the need to balance therapeutic benefits and risks. Further research is crucial for refining clinical applications and understanding TZP’s role in DM2 management across doses.
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Dyspepsia | Eating Disorders & Weight Management | Endocrinology | Gastroenterology | Insulin | Obesity | Statistics | Study | Weight Loss